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Abstract  
Cross-sectional study evaluating the relationship between: a) functional and structural 
measurements of neurodegeneration in initial stages of diabetic retinopathy (DR); and b) 
presence of neurodegeneration and early microvascular impairment. We analyzed baseline 
data of patients with type 2 diabetes (n=449) enrolled in the EUROCONDOR study 
(NCT01726075). Functional studies by multifocal ERG (mfERG) evaluated neurodysfunction 
and structural measurements using spectral domain optical-coherence tomography (SD-OCT) 
evaluated neurodegeneration. The mfERG P1 amplitude was more sensitive than the P1 
implicit time (IT), and was lower in patients with ETDRS 20-35 than in patients with ETDRS 
<20 (p=0.005). In 58% of cases, mfERG abnormalities were present in the absence of visible 
retinopathy. Correspondence between SD-OCT thinning and mfERG abnormalities was 
shown in 67% of the eyes with ETDRS <20 and in 83% of the eyes with ETDRS 20-35. 
Notably, 32% of patients with ETDRS 20-35 presented no abnormalities in mfERG or SD-
OCT. We conclude that there is a link between mfERG and SD-OCT measurements which 
increases with the presence of microvascular impairment. However, in our particular study 
population (ETDRS ≤ 35) a significant proportion of patients had normal GC-IPL thickness 
and normal mfERG findings. We raise the hypothesis that neurodegeneration may play a role 
in the pathogenesis of DR in many, but not in all type 2 diabetic patients. 
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Diabetic retinopathy (DR) is the commonest complication of diabetes and remains the leading 
cause of blindness among working-age individuals in most developed countries (1). Since the 
global incidence of diabetes is set to rise dramatically from an estimated 382 million people in 
2013 to 592 million by 2030 (2), DR will become an even more serious problem in the 
coming years.      
Tight control of blood glucose levels and blood pressure are essential in preventing DR 
development or arresting its progression. However, current treatments for DR are targeted at 
advanced stages when laser photocoagulation, intravitreal injections of anti-VEGF agents or 
corticosteroids and vitreoretinal surgery are implemented. All these treatments are invasive, 
expensive and have a significant number of secondary effects. Therefore, new treatments for 
the early stages of DR are needed (3, 4).  
DR has been classically considered as a microvascular disease of the retina. However, 
growing evidence suggests that retinal neurodegeneration is an early event in the pathogenesis 
of DR, which could contribute to the development of microvascular abnormalities (5-8). It is 
therefore reasonable to hypothesize that therapeutic strategies based on neuroprotection may 
be effective not only in preventing or arresting retinal neurodegeneration, but also in 
preventing the development and progression of the early stages of DR in terms of 
microvascular impairment (3, 8). This opens up the possibility of developing topical therapy 
in the early stages of DR, when currently established therapies such as laser photocoagulation 
or intravitreal injections of corticosteroids or anti-VEGF agents are inappropriate (8-10). 
EUROCONDOR (European Consortium for the Early Treatment of Diabetic Retinopathy) has 
been created in order to implement a large clinical trial (NCT01726075) using eye drops 
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containing brimonidine or somatostatin (two previously demonstrated neuroprotective 
agents), in the early stages of diabetic retinal disease.  
Multifocal electroretinography (mfERG) and spectral domain optical coherence tomography 
(SD-OCT) have both been employed in clinical studies to respectively measure 
neurodysfunction and neurodegeneration. The mfERG has been shown to sensitively detect 
the presence of neuroretinal dysfunction in patients with type 1 diabetes even without any 
detected blood-retinal barrier leakage measured by vitreous fluorometry (11). In addition, and 
more importantly, several authors have found that an increase of the implicit time (IT) in 
mfERG is a predictor for the development of visible vascular abnormalities over 1-year (12, 
13), and 3-year periods (14). However, mfERG is cumbersome for the patient and time-
consuming and, therefore, is only used in the setting of clinical trials. SD-OCT provides 
anatomical and structural information and is widely available, easy to perform and 
comfortable for the patients. However there is little information regarding the relationship 
between mfERG and SD-OCT and the presence of early microvascular impairment.  
On this basis, the aim of the present work was to analyze the relationship between baseline 
mfERG characteristics and structural abnormalities assessed by SD-OCT, taking into account 
the presence and degree of microvascular abnormalities in the early stages of DR.  
Research Design and Methods 
Study Subjects 
The data for this cross-sectional study derived from the 449 patients with type 2 diabetes  with 
either no visible DR (ETDRS level <20) or only early stages of DR (ETDRS level 20-35) 
enrolled in the prospective, multicenter and randomized clinical trial EUROCONDOR 
(NCT01726075). This clinical trial was performed by 11 European ophthalmology clinical 
research centers of the European Consortium for the Early Treatment of Diabetic Retinopathy 
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and funded by the European Commission 7th Framework Programme (Grant Agreement N: 
278040).  
In addition to ETDRS level ≤35, the inclusion criteria were duration of type 2 diabetes for at 
least 5 years and age between 45-75 years. Exclusion criteria included previous laser 
photocoagulation, retinal degeneration-inducing diseases (i.e. glaucoma) and refractive error 
greater than or equal to +/-5 dioptres. Eyes with hazy ocular media or inadequate pupil 
dilatation that prevented good quality fundus photography were excluded. Patients with renal 
failure (creatinine > 124 µmol/L) or A1C > 10% (86 mmol/mol) in the previous 6 months 
were also excluded.  
The study adhered to the tenets of the Declaration of Helsinki and was approved by the 
review boards of each participant country. Written informed consent was obtained from all 
patients before performing any procedures. 
Each patient underwent a comprehensive ophthalmic examination, including a review of the 
medical history, best corrected visual acuity (BCVA) using ETDRS protocol, slit-lamp 
biomicroscopy, intraocular pressure measurement with Goldmann applanation tonometry, 
gonioscopy and dilated funduscopic examination, and fasting blood sampling for blood count 
and biochemistry analysis. In addition, standardized 7-field color fundus photography (CFP), 
SD-OCT and mfERG were performed in all patients. These 3 examinations took place within 
the timeframe of one month and their outputs were graded by a centralized reading center 
(AIBILI CORC – Coimbra Ophthalmology Reading Center). Only one eye from each patient 
was included in the study. If both eyes met the inclusion criteria, one of the eyes was chosen 
randomly.  
Grading data were analyzed in two groups according to severity: patients with ETDRS level 
<20 (without microaneurysms), or patients with ETDRS level 20-35 (mild nonproliferative 
DR).  
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Multifocal ERG Recording and Analysis  
The mfERGs were recorded in the study eye using the RETI-port/scan 21 (Roland Consult, 
Berlin, Germany) visual electrophysiology system. Patients were allowed to eat in order to 
avoid hypoglycemia during the examination. Stimulation and recording of the mfERG 
responses were performed according to the International Society for Clinical 
Electrophysiology of Vision (ISCEV) guidelines (15, 16). After full dilatation of the pupil 
with 1% tropicamide and 2,5% phenylephrine and topical anesthesia, a DTL-plus electrode 
was placed in the lower conjunctival fornix, a reference skin electrode was placed near the 
orbital rim and a ground skin electrode was attached to the forehead. The fellow eye was 
occluded and impedances were checked. The patient had to fixate a large red cross in the 
stimulation monitor and the fixation was controlled using an integral fundus camera using 
infrared illumination. The stimulus array consisted of 103 hexagons displayed at a 60-Hz 
frame rate centered on the fovea covering a visual field of 30º. The luminance of each 
hexagon was independently alternated between black (<2cd/m2 of luminance) and white 
(200cd/m2 of luminance) according to a pseudorandom binary m-sequence. Each recording 
was taken in 12 cycles of approximately 47 seconds each with an artefact rejection level of 
10%. Exams on the baseline visit were rejected when they presented any of the following: 
‘eccentric fixation’; ‘unsteady fixation’; or ‘too much noise compromising the waveform’. 
Sixty-four out of the 449 exams (14%)  had to be retaken for one or more of these reasons. 
After repeats, all exams were of sufficient quality to be included in the study cohort. 
Data corresponding to P1 amplitude and IT of 103 hexagons, organized in 6 concentric rings 
(Figure 1A) obtained in patients with type 2 diabetes were compared with a normative 
database (n= 111 healthy eyes from 76 non-diabetic age-matched controls) which was also 
generated in the setting of the EUROCONDOR project (17). Healthy volunteers recruited for 
the mfERG normative database were checked for diabetes by a review of the medical history 
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with recent blood analysis data. In addition, patients with any known ophthalmic disease were 
excluded. 
OCT Imaging and Analysis 
Spectral Domain OCT (SD-OCT) images were acquired according to standardized acquisition 
protocols by CIRRUS HD-OCT (Zeiss Meditec), henceforth designated as CIRRUS, or by 
Topcon 3D-OCT 2000 (Topcon Corporation), henceforth designated as Topcon, depending on 
the equipment available at each site. A total of 284 patients underwent CIRRUS HD-OCT 
imaging (117 patients with ETDRS level <20 and 167 patients with ETDRS level 20-35), 
while 165 patients underwent Topcon 3D-OCT 2000 imaging (76 patients with ETDRS level 
<20 and 89 patients with ETDRS level 20-35). OCT scans were accepted upon confirmation 
of good quality and the absence of segmentation errors that compromised quantitative 
analysis. Thirteen exams had to be retaken. After the repeats all exams were of sufficient 
quality to be included in the study cohort. 
Macular retinal thickness and macular GCL-IPL thickness were obtained from Macular Cube 
512x128 acquisition of CIRRUS equipment and from 3D Macula 6mm x 6mm acquisition of 
Topcon, both acquired when centered on the fovea.  Peripapillary RNFL thickness was 
obtained from CIRRUS using Optic Disc Cube 200x200 acquisition and from Topcon using 
the 3D Disc 6.0mm x 6.0mm acquisition. 
GCL-IPL and RNFL thicknesses obtained in type 2 diabetic patients were compared with 
normative databases of the respective equipment manufacturers. The presence of either GCL-
IPL or RNFL thinning was considered when the value was below the mean -2 standard 
deviations (SD). The normal RNFL values of the CIRRUS were calculated by determining the 
average value for a 62.5 years old person (the mean age of the population assessed with that 
equipment).  
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To account for differences between Topcon and CIRRUS equipment, mean values of macular 
thickness, macular GCL-IPL thickness and RNFL thickness at the optic disc were tested. A 
conversion factor (mean CIRRUS value divided by mean Topcon value) was then multiplied 
for Topcon measurements. Conversions factors were 1.11, 1.20, and 0.93 for macular retinal 
thickness, macular GCL-IPL thickness, and RNFL thickness at the optic disc, respectively 
(18).  
Topographical coincidence between mfERG abnormalities and SD-OCT impairment 
By superimposing the OCT map of GCL-IPL over the mfERG hexagonal pattern (Figure 
1B), we analysed the mfERG central rings: Ring 1, Ring 2 and Ring 3 (Figure 1A, red-
delimited area). The P1 amplitude and IT were analyzed by the number of abnormal 
hexagons (an altered hexagon was defined as a hexagon with a z-score ≥2 for IT and ≤-2 for 
amplitude). The relationship between the presence of abnormal hexagons and thinning of the 
GCL-IPL and RNFL layers was examined. 
An eye with a central mfERG abnormality was defined as having at least one abnormal 
hexagon in any of the three central rings (Figure 1). 
 
Statistical Analysis 
Descriptive statistics were calculated for all variables. Differences between normal values of 
mfERG amplitude and IT were inferred with one way analysis of variance (ANOVA). The 
correlation between mfERG or GCL-IPL/RNFL thickness parameters and age, diabetes 
duration and HbA1C was explored with multivariate logistic regression. The relationship 
between abnormalities in central mfERG parameters and thinning of GCL-IPL and/or RNFL 
was explored with chi-square test. Multiple comparison corrections (Bonferroni) were 
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performed where indicated. Statistical analysis was performed with Stata 12.1 (StataCorp LP, 
College Station, TX, USA) and significance was set at 0.05. 
 
Results 
General description 
Four hundred and forty-nine patients with type 2 diabetes were included in this cross-
sectional analysis of the baseline data from the EUROCONDOR cohort. The main clinical 
characteristics of the patients, taking into account the ETDRS levels are displayed in Table 1.  
mfERG abnormalities  
A total of 27 out of 111 non-diabetic control population (24.3%) presented P1 amplitude or 
implicit time abnormal values in at least one of the 19 hexagons that constitute the 3 central 
rings. 
Diabetic patients presented a significantly delayed P1 IT from rings 3-6 (p<0.001) in 
comparison with age-matched non-diabetic control group (Table 2). We found no influence 
of ETDRS levels on P1 IT. Furthermore, the mean IT (ms) of the 6 rings was similar in type 2 
diabetic patients with ETDRS level <20 or ETDRS level 20-35 (36.66 ±1.76 vs. 36.64±1.76; 
p=n.s). 
The mean values of P1 amplitude were significantly lower in the diabetic patients than in the 
control group in all rings (all p<0.001), and the differences were even higher in patients with 
ETDRS level 20-35 than in patients without microangiopathic abnormalities (ETDRS <20) 
(Table 2). Thus, the mean amplitude (nV/deg2) was significantly higher in patients with type 
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2 diabetes with ETDRS <20 in comparison with those with ETDRS 20-35 (45.96 ± 12.29 vs. 
42.77 ± 11.29; p=0.006). 
 The difference in P1 amplitude between central and peripheral retina (ring 1-ring 6) was 
significantly reduced in type 2 diabetic patients in comparison with non-diabetic subjects 
(99±35 nV/deg2 vs. 109±26 nV/deg2; p<0.001).  
Age was correlated with P1 IT (r=0.206; p<0.001) but no relationship was found between P1 
IT or amplitude with diabetes duration or HbA1C levels. 
Finally, the 58% of diabetic patients with ETDRS <20 presented abnormalities in central 
mfERG, and this percentage increase to 66% in diabetic patients with ETDRS 20-35 (p=0.07).  
SD-OCT abnormalities 
The average thickness of the macular GCL-IPL complex and the average thickness of the 
peripapillary RNFL were analyzed in the two DR study groups (ETDRS <20 and ETDRS 20-
35) and compared with the normal thickness values given by the normative databases 
provided by the equipment manufacturers. The homogenized results obtained after applying 
the conversion factors previously mentioned are shown in Table 3.  
The average GCL-IPL thickness was significantly lower in eyes of patients with diabetes 
when compared to the normal population (79.4±7.3 µm vs. 82.1±6.2 µm; p<0.001); but there 
was no difference among patients with different ETDRS levels (Table 3; p=n.s). Conversely, 
average RNFL at the optic disc presented no significant differences between patients’ eyes 
and the normal population (89.1±9.7 µm vs. 89.8±8.5 µm; p=n.s). A total of 41 patients with 
type 2 diabetes (9.1%) presented values of GCL-IPL or RNFL below the normal range.  
We found that patients with type 2 diabetes with ETDRS 20-35 presented values of GCL-IPL 
thickness higher than patients with ETDRS <20 (p=0.018). However, when the crude data 
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were corrected taking into account total retinal thickness no relationship between GCL-IPL 
thickness and ETDRS levels was found. 
Age was negatively correlated with the average thicknesses of both GCL-IPL (r=-0.27; 
p<0.001) and RNFL (r=-0.17; p<0.001). However, no correlations were found between GCL-
IPL or RNFL thickness and diabetes duration or HbA1C levels. 
Relationship between SD-OCT and mfERG 
In the 193 eyes classified as having ETDRS level <20 (i.e. with no apparent microvascular 
abnormalities), central P1 mfERG abnormalities of amplitude or IT were present in 58% of 
eyes and there was a decrease below the normal values of GCL-IPL or RNFL layers thickness 
in only 9% of the eyes. Similarly, eyes with ETDRS levels 20-35 (with microvascular 
changes) (n=256) showed central mfERG abnormalities of amplitude or IT in 66% of cases 
and thinning of GCL-IPL or RNFL in 9%. 
The relationship between abnormalities in central mfERG parameters and thinning of GCL-
IPL and/or RNFL is displayed in Table 4. In patients with ETDRS < 20, 67% of the cases 
with GCL-IPL or RNFL thinning also presented mfERG abnormalities. However, in patients 
with ETDRS 20-35, 83% of the cases with GCL-IPL or RNFL thinning also presented 
mfERG abnormalities (p=0.07). 
Relationship between measurements related to neurodegeneration and early microvascular 
impairment 
The relationship between the measurements related to neurodysfunction and/or 
neurodegeneration according to ETDRS levels are shown in Table 5. We found that 61% of 
patients with ETDRS <20 presented neurodysfunction/neurodegeneration and 68% in patients 
with ETDRS 20-35 (Chi square: p=0.13). Therefore, neurodegeneration/neurodysfunction 
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abnormalities did not significantly increase in presence of microvascular abnormalities but, as 
previously mentioned, this latter condition favored the clustering between mfERG and SD-
OCT.  
It should be noted that 82 of 256 patients with ETDRS 20-35 (32%) did not present any 
abnormalities in mfERG or SD-OCT examinations, thus suggesting the presence of primarily 
a microvascular or a microangiopathic phenotype. On the other hand 118 out of 193 patients 
(61%) without visible microvascular lesions (ETDRS<20) presented abnormalities related to 
neurodegeneration assessed by either mfERG (58%) or SD-OCT (9%), thus suggesting a 
neurodysfunctional or neurodegenerative phenotype.  
 
Discussion 
The EUROCONDOR study was designed to test the potential role of two different 
neuroprotective agents in arresting the progression of retinal neurodegeneration in the diabetic 
retina. The major functional test chosen to identify and follow neurodegeneration was mfERG 
and structural abnormalities were evaluated by SD-OCT. In this report, the baseline data have 
been evaluated in order to study the relationship between neurodegeneration assessed by 
mfERG (functional abnormalities) and SD-OCT (structural damage), as well as their 
relationship with the absence (ETDRS level <20) or presence (ETDRS levels 20-35) of early 
microvascular retinal impairment.  
Multifocal ERG is a highly sensitive method which allows for an objective and quantitative 
measurement of retinal function. When this technique is performed following a well-defined 
protocol by trained examiners, it offers reliable results, and may be particularly valuable for 
evaluating retinal neuron impairment. The baseline data collected from EUROCONDOR 
participants showed alterations of the mfERG in almost 60% of type 2 diabetic patients with 
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no apparent fundus abnormalities (ETDRS level <20). These findings are in agreement with 
previous studies (11-14), and support the concept that functional impairment related to 
neurodegeneration is an early event in the diabetic retina. However, in 34% of diabetic 
patients with early microvascular impairment (ETDRS 20-35) mfERG abnormalities were not 
found. Therefore, it seems that in some of these patients, retinal neurodegeneration does not 
appear to play an essential role in the development of DR, at least when assessed by mfERG. 
The most widely used mfERG parameter in the setting of diabetes has been the P1 Implicit 
Time (IT) because of its lower variability in comparison to P1 amplitude. However, our 
results provide evidence that P1 amplitude, rather than P1 IT, is the most sensitive parameter. 
We found a decrease of P1 amplitude from the central to the peripheral retina (from ring 1 to 
ring 6) in both type 2 diabetic patients and healthy controls. Our results agree with previous 
studies performed in Indian (19) and Japanese (20) normal subjects. The geographical 
distribution of cones (higher in the central retina and lower in the periphery) supports these 
findings (21, 22). Our results suggest that the difference in P1 amplitude from the central to 
the peripheral retina could be a useful parameter for monitoring the neurodegenerative 
process, but further studies to examine this issue are needed.   
One important issue to be considered when analyzing mfERG is the fluctuation response that 
could occur depending on the glycemic excursions. In the present study, patients with poor 
glycemic control (HbA1c >10%) were excluded, the mean fasting glucose was 7.99 mmol/L ± 
SD 2.89, HbA1c was 7.1% ± SD 1.0 (55 mmol/mol ± SD 10.9) and, more importantly, we did 
not observe any relationship between fasting glycemia or HbA1c levels with mfERG 
abnormalities. For all these reasons, a potential influence of glycemic fluctuations on mfERG 
seems very unlikely. 
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The most important structural damage of the retina detected by SD-OCT was a thinning of the 
GCL-IPL and RNFL layers, although in far fewer number of eyes/patients in comparison with 
mfERG abnormalities. However, mfERG abnormalities were absent in around 1/3 of patients 
with ETDRS level <20 in whom GCL-IPL or RNFL thickness were below the normal range. 
In this regard, it should be noted that mfERG is a measurement of cone photoreceptor and 
bipolar cell function (22), and may not represent inner retinal defects. Therefore, the observed 
dissociation between the two tests is not entirely surprising. In addition, whereas the thinning 
of the neuroretina assessed by SD-OCT reflects neural loss, mfERG abnormalities could only 
be the consequence of neurodysfunction due to glial activation. This finding supports the 
complementarity of using both examinations when neurodysfunction/neurodegeneration is 
being assessed. One result that merits to be commented on is the absence of further GCL-IPL 
or RNFL thickness reduction when microangiopathy was detected, whereas P1 amplitude was 
significantly reduced. In fact, an increase of GCL-IPL thickness was detected in patients with 
ETDRS 20-35 in comparison with patients with ETDRS <20. This could be attributed to the 
increased sensitivity of functional mfERG rather than structural SD-OCT abnormalities when 
assessing the neurodegenerative process. However, it is also possible that vascular leakage 
predominant in the inner nuclear layers (INL) in the initial stages of diabetic retinal disease 
leads to an increase in overall thickness of the retina, acting as a confounding factor which 
masks thinning of the GCL-IPL complex. In a recent study, where a large cohort of diabetic 
eyes with non-proliferative retinopathy was followed for one year, thinning of GCL-IPL and 
RNFL was also found. But this increase in thinning was masked by the presence of retinal 
edema resulting from leakage from the retinal vessels and increase in the retinal extracellular 
space extending to the inner retinal layers (23). In this regard, in our study when the GCL-IPL 
thickness was corrected by taking into account total retinal thickness, the inverse relationship 
between GCL-IPL thickness and progression from ETDRS <20 to ETDRS 20-35 disappeared.   
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Both mfERG and SD-OCT abnormalities were related to age. This finding was expected due 
to the direct relationship between the neurodegenerative process and age. The lack of 
association between mfERG and SD-OCT measurements of neurodegeneration and HbA1C 
could be attributed to the well-established concept that HbA1c levels taken at a certain point 
in time do not necessarily represent the previous history of metabolic control of the patient 
and, therefore, biomarkers of long-term glycation might be more informative than HbA1C 
levels. In addition, the excellent control of blood glucose levels in this cohort (mean HbA1C = 
7.16% [55.2 mmol/mol] and only 30% patients over 7.5% [58.5 mmol/mol]) could also have 
contributed to this result.   
Little is known regarding the relationship between functional and structural abnormalities in 
the setting of diabetes-induced retinal neurodegeneration. In the present study we have found 
an impairment of the retinal function in the initial stages of retinal disease in type 2 diabetic 
patients with a good correspondence between central mfERG changes (3 central rings) and 
SD-OCT structural damage (thinning of GCL-IPL and RNFL layers), which increased with 
the presence of early DR. As previously reported in this cohort, these neuroretinal 
abnormalities have clinical implications in terms of vision related quality of life (24). 
It is notable that 32% of the patients with visible microvascular disease in color fundus 
photography (ETDRS 20-35) did not present any functional or structural abnormality related 
to neurodegeneration. This finding suggests the presence of a significant proportion of 
patients with a primarily microvascular or microangiopathic phenotype, in which the role of 
neurodegeneration remains to be elucidated. On the other hand 61% of the patients without 
visible microvascular disease (ETDRS<20) presented abnormalities related to 
neurodegeneration assessed by either mfERG or SD-OCT, thus suggesting the presence of a 
neurodysfunctional or neurodegenerative phenotype. Prospective follow up will determine 
whether this phenotype will be more prone to develop microvascular disease than in those 
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patients without neurodegenerative abnormalities. The identification of these two phenotypes 
is an important issue because of its therapeutic implications, particularly when analyzing the 
potential effect of neuroprotective agents.  
In conclusion, functional abnormalities can be detected by mfERG in almost 60% of type 2 
diabetic patients with no apparent fundus abnormalities and these changes antedate the 
structural damage measured by SD-OCT. However, this is not a universal pattern and in a 
significant proportion of these patients the development of microvascular disease is not 
preceded by any neurodegenerative abnormality detected via the methods used in this study 
(SD-OCT and mfERG). Overall our findings open up the hypothesis that neurodegeneration 
could play a role in the pathogenesis of early stages of DR in a large proportion, but not in all 
type 2 diabetic patients.  
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FIGURE LEGENDS 
 
Figure 1: A. Diagram of the stimulus array used to elicit the multifocal ERGs. Stimulus 
consisted of 103 hexagons, organized in 6 concentric rings, scaled (not represented) to elicit 
similar amplitudes at all locations. B. Superimposition of the mfERG stimulus array and the 
SD-OCT (GCL+IPL) elliptical annulus grid (blue) on a fundus image, centered on the fovea. 
The green-contoured hexagon represents the central mfERG hexagon, and the two grey circles 
represent the 10º and 20º of the mfERG grid. 
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Table 1. Demographic characteristics of study patients 
 
 Total 
N=449 
ETDRS <20 
(n=193) 
ETDRS 20-35 
(n=256) 
p* 
Age (years) 62.82±6.70 64.32±6.40 61.70±6.80 <0.001 
Gender (% males) 65.9 70.5 62.5 n.s 
Diabetes duration (years) 11.66±5.60 10.57±5.10 12.48±5.90 <0.001 
Fasting blood glucose  (mg/ml) 
(mmol/L) 
144±52 
7.99±2.89 
137±46 
7.60±2.55 
149±55 
8.27±3.05 
0.018 
HbA1C (%) 
 (mmol/mol) 
7.16±1.00  
(55±10.9) 
7.01±0.90 
(53±9.9) 
7.28±1.10 
(56±11.5) 
0.006 
Hypertension (%) 73.3 73.1 73.4 n.s 
Dyslipidemia (%) 70.8 74.1 68.4 n.s 
Current smokers (%) 13.4 13.5 13.3 n.s 
Microalbuminuria (%) 12.9 11.7 13.7 n.s 
Cardiovascular disease (%) 20.3 22.3 18.8 n.s 
BCVA letters Score 86.14±5.10 85.78±5.40 86.42±4.80 n.s 
* p value between ETDRS <20 and ETDRS 20-35 
Data are expressed as mean±SD. Hypertension was defined as systolic blood pressure/diastolic blood 
pressure ≥140/90 mmHg or current treatment with antihypertensive drugs. Dyslipidemia was defined 
following the American Diabetes Association criteria. Cardiovascular disease was defined as a 
composite endpoint including coronary artery disease, peripheral artery disease and cerebrovascular 
disease either self-reported or diagnosed by a physician. 
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Table 2. Values of P1 implicit time and amplitude (mean±SD) of the six concentric rings in 
healthy controls and type 2 diabetic patients. 
 
  
Ring 
Healthy 
controls 
(n=76) 
ETDRS <20  
(n=193) 
ETDRS 20-35  
(n= 256) 
 
P* 
 1 42.0±3.5 42.1±4.7 42.1±4.7 0.63 
 2 36.0±2.0 36.6±2.9 36.6±2.8 0.08 
Implicit Time 3 34.2±1.8† 35.6±2.0 35.6±1.7 <0.001 
(ms) 4 33.5±1.8 † 35.0±1.7 35.1±1.7 <0.001 
 5 33.4±1.7 † 35.0±1.7 35.1±1.9 <0.001 
 6 33.8±1.8 † 35.3±1.9 35.4±1.7 <0.001 
 1 128.9±26.4 † 118.4±40.1 111.5±35.8 <0.001 
 2 70.2±13.3† 56.3±16.1‡ 52.6±14.6§ <0.001 
Amplitude 3 46.8±8.3† 37.7±10.7‡ 34.5±9.1§ <0.001 
(nV/deg
2
) 4 32.6±5.7† 26.7±8.1‡ 24.4±6.8§ <0.001 
 5 25.0±4.7† 20.5±6.4‡ 18.8±5.5§ <0.001 
 6 20.3±4.0† 16.3±5.4 15.3±5 <0.001 
 
* p value from ANOVA 
† significantly different from ETDRS <20 and ETDRS 20-35 
‡ significantly different from Healthy controls and ETDRS 20-35 
§ significantly different from Healthy controls and ETDRS <20 
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Table 3. SD-OCT values considering DR severity level 
 
 Healthy subjects 
N=282* 
ETDRS <20 
N=193 
ETDRS 20-35 
N=256 
All patients 
N=449 
 
GCL-IPL (µm) 
 
82.1±6.2 
 
78.6±7.3† 
 
79.7±7.7† 
 
79.4±7.3‡ 
 
 
RNFL (µm) 
 
89.8±8.5 
 
88.6±10.3 
 
89.9±9.8 
 
89.1±9.7 
 
* Data referred from normative database of the manufacturers 
† Significantly different from healthy subjects on an independent samples t-test for p<0.025 
(Bonferroni correction for multiple comparisons) 
‡ Significantly different from healthy subjects on an independent samples t-test for p<0.05. 
Data are mean±SD 
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Table 4.  Correspondence between abnormalities in central mfERG and SD-OCT parameters. 
 
 All patients (n=449)  
 Normal mfERG 
N (%) 
Abnormal mfERG 
N (%) 
Normal SD-OCT, n (%) 160 (35.6) 248 (55.2) 
Abnormal SD-OCT, n (%) 10 (2.2) 31 (6.9) 
 p= 0.06 
                            ETDRS <20 (n=193) 
Normal SD-OCT, n (%) 76 (39.4) 99 (51.3)  
Abnormal SD-OCT, n (%) 6 (3.1) 12 (6.2) 
   p= 0.41 
                           ETDRS 20-35 (n=256) 
Normal SD-OCT, n (%) 84 (32.8) 149 (58.2)  
Abnormal SD-OCT, n (%) 4 (1.6) 19 (7.4) 
   p= 0.07 
 
 
 
 
 
 
 
 
 
 
Page 28 of 30Diabetes
28 
 
 
Table 5. Relationship between the measurements related to neurodysfunction and/or 
neurodegeneration according to ETDRS levels 
 
 No Microangiopathy 
ETDRS <20 
N=193 
Microangiopathy 
ETDRS 20-35 
N=256 
 No NRD NRD  No NRD NRD  
N (%) 75 (39) 118 (61)  82 (32) 174 (68)  
Age (years) 63.1±6.7 65.1±6.0 0.04 59.7±7.5 62.6±6.1 0.003 
BMI (Kg/m2) 30 31 ns 30 30 ns 
Diabetes duration (years) 11±5.5 10.3±4.8 ns 11.8±4.8 12.8±6.3 ns 
Fasting blood glucose (mg/dL) 
(mmol/L)  
129±44 
7.16±2.44 
142±47 
7.88±2.61 
0.07 148±56 
8.21±3.11 
149±55 
8.27±3.05 
ns 
HbA1c (%) 
(mmol/mol) 
7.05±0.79 
54 ±8.7 
6.98±0.96 
53 ±10.6 
ns 7.16±0.98 
55 ±10.7 
7.32±1.08 
56 ±11.3 
ns 
Mean IT (ms) 36.16±1.41 36.96±1.88 0.001 35.93±1.41 36.98±1.81 <0.001 
Mean A (nV/deg2) 51.35±11.11 42.56±12.89 0.012 48.61±9.00 40.12±11.22 <0.001 
GCL-IPL (µm) 80.47±5.92 77.39±7.77 0.004 82.09±6.77 78.66±7.90 0.001 
RNFL (µm) 90.70±9.17 87.35±9.67 0.018 92.18±8.31 88.22±10.28 0.003 
 
NRD: neurodysfunction and/or neurodegeneration 
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 Supplemental Material 
mfERG standardization 
Consistency of outcomes across multiple testing sites was ensured through appropriate 
training and consistent monitoring of mfERG outcomes to maintain quality assurance 
standards. In order to ensure appropriate quality of participation, an acquisition protocol 
was created and all clinical sites used the same equipment (RETI-port/scan21 – Roland 
Consult) set up with fixed acquisition parameters. At least one technician from all 11 
sites received specialized training at Coimbra Ophthalmology Reading Centre to learn 
the acquisition protocol and to ensure consistency of the examination technique. In 
addition, all sites received individualized on-site refresher training following specialized 
training. Before acquiring any EUROCONDOR study exams, each technician 
performed four mfERG examinations (four eyes) according to the acquisition protocol 
that was reviewed by CORC to ensure quality exams and certify the technicians. 
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